Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects

J. E. Gadek, H. G. Klein, P. V. Holland, Ronald Crystal

Research output: Contribution to journalArticle

169 Citations (Scopus)

Abstract

The emphysema associated with the inherited serum deficiency of α1-antitrypsin appears to result from an imbalance between neutrophil elastase and its major inhibitor within the alveolar structures. In the present study we assessed the feasibility of reversing this biochemical defect within the lung via parenteral replacement therapy with an α1-antitrypsin concentrate of normal plasma. A 20-40% polyethylene glycol precipitate of pooled human donor plasma was used to obtain an enriched α1-antitrypsin concentrate devoid of hepatitis B antigen and immunoglobulin. Using this material, five individuals with severe serum α1-antitrypsin deficiency (PiZ phenotype) and advanced emphysema received 4 g of α1-antitrypsin intravenously at weekly intervals for four doses. During this period of weekly replacement therapy α1-antitrypsin serum levels were maintained at ≥70 mg/dl, the level likely required for effective antielastase protection of the lung. In addition, assessment of lower respiratory tract antielastase activity by bronchoalveolar lavage demonstrated that parenteral replacement of α1-antitrypsin resulted in establishment of effective anti-elastase activity within the alveolar stuctures. There were no untoward side effects consequent to this approach to the replacement therapy of α1-antitrypsin. These results demonstrate that the parenteral replacement of α1-antitrypsin provides a means of obtaining elastase-antielastase balance within the lung of individuals with this serum protease inhibited deficiency.

Original languageEnglish
Pages (from-to)1158-1165
Number of pages8
JournalJournal of Clinical Investigation
Volume68
Issue number5
DOIs
Publication statusPublished - 1 Jan 1981
Externally publishedYes

Fingerprint

alpha 1-Antitrypsin Deficiency
Protease Inhibitors
Peptide Hydrolases
Pancreatic Elastase
Emphysema
Serum
Lung
Hepatitis B Antigens
Leukocyte Elastase
Feasibility Studies
Bronchoalveolar Lavage
Therapeutics
Respiratory System
Immunoglobulins
Phenotype
Autosomal Recessive alpha-1-Antitrypsin Deficiency

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. / Gadek, J. E.; Klein, H. G.; Holland, P. V.; Crystal, Ronald.

In: Journal of Clinical Investigation, Vol. 68, No. 5, 01.01.1981, p. 1158-1165.

Research output: Contribution to journalArticle

@article{6da90fbb92f9431a9e3d618d9311db91,
title = "Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects",
abstract = "The emphysema associated with the inherited serum deficiency of α1-antitrypsin appears to result from an imbalance between neutrophil elastase and its major inhibitor within the alveolar structures. In the present study we assessed the feasibility of reversing this biochemical defect within the lung via parenteral replacement therapy with an α1-antitrypsin concentrate of normal plasma. A 20-40{\%} polyethylene glycol precipitate of pooled human donor plasma was used to obtain an enriched α1-antitrypsin concentrate devoid of hepatitis B antigen and immunoglobulin. Using this material, five individuals with severe serum α1-antitrypsin deficiency (PiZ phenotype) and advanced emphysema received 4 g of α1-antitrypsin intravenously at weekly intervals for four doses. During this period of weekly replacement therapy α1-antitrypsin serum levels were maintained at ≥70 mg/dl, the level likely required for effective antielastase protection of the lung. In addition, assessment of lower respiratory tract antielastase activity by bronchoalveolar lavage demonstrated that parenteral replacement of α1-antitrypsin resulted in establishment of effective anti-elastase activity within the alveolar stuctures. There were no untoward side effects consequent to this approach to the replacement therapy of α1-antitrypsin. These results demonstrate that the parenteral replacement of α1-antitrypsin provides a means of obtaining elastase-antielastase balance within the lung of individuals with this serum protease inhibited deficiency.",
author = "Gadek, {J. E.} and Klein, {H. G.} and Holland, {P. V.} and Ronald Crystal",
year = "1981",
month = "1",
day = "1",
doi = "10.1172/JCI110360",
language = "English",
volume = "68",
pages = "1158--1165",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "5",

}

TY - JOUR

T1 - Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects

AU - Gadek, J. E.

AU - Klein, H. G.

AU - Holland, P. V.

AU - Crystal, Ronald

PY - 1981/1/1

Y1 - 1981/1/1

N2 - The emphysema associated with the inherited serum deficiency of α1-antitrypsin appears to result from an imbalance between neutrophil elastase and its major inhibitor within the alveolar structures. In the present study we assessed the feasibility of reversing this biochemical defect within the lung via parenteral replacement therapy with an α1-antitrypsin concentrate of normal plasma. A 20-40% polyethylene glycol precipitate of pooled human donor plasma was used to obtain an enriched α1-antitrypsin concentrate devoid of hepatitis B antigen and immunoglobulin. Using this material, five individuals with severe serum α1-antitrypsin deficiency (PiZ phenotype) and advanced emphysema received 4 g of α1-antitrypsin intravenously at weekly intervals for four doses. During this period of weekly replacement therapy α1-antitrypsin serum levels were maintained at ≥70 mg/dl, the level likely required for effective antielastase protection of the lung. In addition, assessment of lower respiratory tract antielastase activity by bronchoalveolar lavage demonstrated that parenteral replacement of α1-antitrypsin resulted in establishment of effective anti-elastase activity within the alveolar stuctures. There were no untoward side effects consequent to this approach to the replacement therapy of α1-antitrypsin. These results demonstrate that the parenteral replacement of α1-antitrypsin provides a means of obtaining elastase-antielastase balance within the lung of individuals with this serum protease inhibited deficiency.

AB - The emphysema associated with the inherited serum deficiency of α1-antitrypsin appears to result from an imbalance between neutrophil elastase and its major inhibitor within the alveolar structures. In the present study we assessed the feasibility of reversing this biochemical defect within the lung via parenteral replacement therapy with an α1-antitrypsin concentrate of normal plasma. A 20-40% polyethylene glycol precipitate of pooled human donor plasma was used to obtain an enriched α1-antitrypsin concentrate devoid of hepatitis B antigen and immunoglobulin. Using this material, five individuals with severe serum α1-antitrypsin deficiency (PiZ phenotype) and advanced emphysema received 4 g of α1-antitrypsin intravenously at weekly intervals for four doses. During this period of weekly replacement therapy α1-antitrypsin serum levels were maintained at ≥70 mg/dl, the level likely required for effective antielastase protection of the lung. In addition, assessment of lower respiratory tract antielastase activity by bronchoalveolar lavage demonstrated that parenteral replacement of α1-antitrypsin resulted in establishment of effective anti-elastase activity within the alveolar stuctures. There were no untoward side effects consequent to this approach to the replacement therapy of α1-antitrypsin. These results demonstrate that the parenteral replacement of α1-antitrypsin provides a means of obtaining elastase-antielastase balance within the lung of individuals with this serum protease inhibited deficiency.

UR - http://www.scopus.com/inward/record.url?scp=0019787989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019787989&partnerID=8YFLogxK

U2 - 10.1172/JCI110360

DO - 10.1172/JCI110360

M3 - Article

VL - 68

SP - 1158

EP - 1165

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 5

ER -